Segment Disclosures (Tables)

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

Schedule of Significant Expense

The table below summarizes the significant expense categories regularly reviewed by the CODM for the three and nine months ended September 30:

	Three Months Ended September 30,
	2026		2025
Operating expenses:
Clinical product candidates	$	16,881	$	15,285
Pre-clinical product candidates	599		480
Employee costs- research and development	3,846		2,463
Employee costs-general and administrative	2,997		1,661
Non-cash stock compensation	13,908		3,614
Depreciation expense	38		40
Professional fees and other segment expenses	5,100		2,450
Total operating expenses	43,369		25,993
Loss from operations	(43,369)		(25,993)
Interest income	1,093		419
Other income (expense)	(33)		(5)
Net loss	$	(42,309)	$	(25,579)
	Nine Months Ended September 30,
	2026		2025
Operating expenses:
Clinical product candidates	$	55,193	$	50,776
Pre-clinical product candidates	1,522		825
Employee costs- research and development	10,218		7,224
Employee costs-general and administrative	7,257		5,305
Non-cash stock compensation	25,156		7,555
Depreciation expense	105		126
Professional fees and other segment expenses	12,480		8,090
Total operating expenses	111,931		79,901
Loss from operations	(111,931)		(79,901)
Interest income	3,139		843
Other income (expense)	(204)		1,186
Net loss	$	(108,996)	$	(77,872)